• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
AEterna Zentaris Inc. - Product Pipeline Review - Q1 2011 Product Image

AEterna Zentaris Inc. - Product Pipeline Review - Q1 2011

  • Published: March 2011
  • Region: Global
  • 104 pages
  • Global Markets Direct

AEterna Zentaris Inc. – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “AEterna Zentaris Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- AEterna Zentaris Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of AEterna Zentaris Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment READ MORE >



List of Tables
List of Figures
AEterna Zentaris Inc. Snapshot
AEterna Zentaris Inc. Overview
Key Information
Key Facts
AEterna Zentaris Inc. – Research and Development Overview
Key Therapeutic Areas
AEterna Zentaris Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
AEterna Zentaris Inc. – Pipeline Products Glance
AEterna Zentaris Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
AEterna Zentaris Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
AEterna Zentaris Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
AEterna Zentaris Inc. – Drug Profiles
KRX-0401 + Velcade
Product Description
Mechanism of Action
R&D Progress
Perifosine
Product Description
Mechanism of Action
R&D Progress
Perifosine + Bortezomib + Dexamethasone
Product Description
Mechanism of Action
R&D Progress
Perifosine + Xeloda
Product Description
Mechanism of Action
R&D Progress
AEZS-105
Product Description
Mechanism of Action
R&D Progress
AEZS-108
Product Description
Mechanism of Action
R&D Progress
Perifosine
Product Description
Mechanism of Action
R&D Progress
AEZS-112
Product Description
Mechanism of Action
R&D Progress
Solorel
Product Description
Mechanism of Action
R&D Progress
AEZS-115
Product Description
Mechanism of Action
R&D Progress
AEZS-120
Product Description
Mechanism of Action
R&D Progress
AEZS-123
Product Description
Mechanism of Action
R&D Progress
AEZS-126
Product Description
Mechanism of Action
R&D Progress
AEZS-127
Product Description
Mechanism of Action
R&D Progress
AEZS-129
Product Description
Mechanism of Action
R&D Progress
AEZS-131
Product Description
Mechanism of Action
R&D Progress
AEZS-132
Product Description
Mechanism of Action
R&D Progress
AEterna Zentaris Inc. – Pipeline Analysis
AEterna Zentaris Inc. – Pipeline Products by Therapeutic Class
AEterna Zentaris Inc. - Pipeline Products By Target
AEterna Zentaris Inc. – Pipeline Products by Route of Administration
AEterna Zentaris Inc. – Pipeline Products by Molecule Type
AEterna Zentaris Inc. – Recent Pipeline Updates
AEterna Zentaris Inc. - Dormant Projects
AEterna Zentaris Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Cetrorelix
AEterna Zentaris Inc. – Company Statement
AEterna Zentaris Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Dec 20, 2010: Aeterna Zentaris Receives Agreement From FDA On SPA For Solorel In Adult Growth Hormone Deficiency Study
Dec 06, 2010: Aeterna Zentaris Presents Phase II Data Of Perifosine In Combination With Sorafenib In Advanced Leukemia And Lymphoma
Dec 06, 2010: Aeterna Zentaris Presents Phase II Data Of Perifosine In Combination With Sorafenib In Advanced Leukemia And Lymphoma
Dec 06, 2010: Aeterna Zentaris Reports Preclinical And Interim Results Of Phase II Of Perifosine In Treatment Of Advanced Leukemia
Dec 06, 2010: Aeterna Zentaris Annoucnes Phase I Results Of Perifosine In Combination With Lenalidomide And Dexamethasone In Multiple Myeloma
Dec 02, 2010: Keryx To Present Data On KRX-0401 At American Society Of Hematology
Dec 02, 2010: Keryx To Present Data On KRX-0401 At American Society Of Hematology
Dec 02, 2010: Keryx To Present Data On KRX-0401 At American Society Of Hematology
Nov 18, 2010: Aeterna Zentaris Reports Positive Phase II Efficacy And Safety Data For AEZS-108 In Advanced Endometrial Cancer
Nov 10, 2010: Aeterna Zentaris To Present Phase II Results For AEZS-108 In Endometrial Cancer At Major Conference In Germany
Financial Deals Landscape
AEterna Zentaris Inc., Deals Volume Summary, 2004 to YTD 2011
AEterna Zentaris Inc., Deals Summary By Region, 2004 to YTD 2011
AEterna Zentaris Inc., Deals Summary, 2004 to YTD 2011
AEterna Zentaris Inc. Detailed Deal Summary
Asset Purchase
AEterna Zentaris Acquires AEZS-130 Assets From Ardana Biosciences
Acquisition
Atrium Innovations Acquires Multicare
Frontier Scientific Acquires Echelon Biosciences From AEterna Zentaris
AEterna Zentaris Acquires Echelon Biosciences
Equity Offering
AEterna Zentaris Completes Registered Direct Offering Of $5.5 Million
AEterna Zentaris Completes Registered Direct Offering Of $10 Million
AEterna Zentaris Enters Into Development Agreement With Keryx Biopharmaceuticals
AEterna Partners With The University Of Montreal
AEterna Zentaris Enters Into Research Collaboration With Julius-Maximilians-University
AEterna Zentaris Enters Into Co-Development With Solvay Pharmaceuticals
AEterna Zentaris Enters Into Co-Development Agreement With University of Montpellier
AEterna Zentaris Enters Into Agreement With The University of Milan
AEterna Zentaris Enters Into Agreement With Roche
AEterna Enters Into Collaboration Agreement With Solvay Pharmaceuticals
AEterna Zentaris Terminates Co-Development Agreement With Solvay
AEterna Zentaris Terminates Agreement With Nippon Kayaku
AEterna Terminates Co-Marketing Agreement With Medac
Asset Finance
Guangdong Yudean Shibeishan Wind Power Development Completes Project Financing For Shibeishan Wind Power Project In Guangdong Province, China
Licensing Agreements
Aeterna Enters Into Licensing Agreement With Sanofi-Aventis
AEterna Enters Into Licensing Agreement With HANDOK Pharmaceuticals
AEterna Enters Into Licensing Agreement With Atani
AEterna Enters Into License And Collaboration Agreement With Nippon Kayaku For Ozarelix
AEterna Enters Into License And Collaboration Agreement With Tulane University
AEterna Zentaris Enters Into Licensing Agreement With Keryx Biopharmaceuticals
AEterna Zentaris Enters Into Licensing Agreement With Spectrum Pharmaceuticals
Aeterna Terminates Commercialization And Licensing Agreement With Sanofi-Aventis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
AEterna Zentaris Inc. – Pipeline by Therapy Area and Indication, 2011
AEterna Zentaris Inc. – Pipeline by Stage of Development, 2011
AEterna Zentaris Inc. – Monotherapy Products in Pipeline, 2011
AEterna Zentaris Inc. – Combination Treatment Modalities in Pipeline, 2011
AEterna Zentaris Inc. – Phase III, 2011
AEterna Zentaris Inc. - Phase II, 2011
AEterna Zentaris Inc. - Phase I, 2011
AEterna Zentaris Inc. - Pipeline By Therapeutic Class, 2011
AEterna Zentaris Inc. - Pipeline By Target, 2011
AEterna Zentaris Inc. – Pipeline By Route of Administration, 2011
AEterna Zentaris Inc. – Pipeline By Molecule Type, 2011
AEterna Zentaris Inc. – Recent Pipeline Updates, 2011
AEterna Zentaris Inc. - Dormant Developmental Projects, 2010
AEterna Zentaris Inc. - Discontinued Pipeline Products, 2010
AEterna Zentaris Inc., Subsidiaries
AEterna Zentaris Inc., Deals Summary, 2004 to YTD 2011
AEterna Zentaris Inc., Deals Summary by Region, 2004 to YTD 2011
AEterna Zentaris Inc., Deals Summary, 2004 to YTD 2011

List of Figures
AEterna Zentaris Inc. – Pipeline by Therapy Area and Indication, 2011
AEterna Zentaris Inc. – Pipeline by Stage of Development, 2011
AEterna Zentaris Inc. – Monotherapy Products in Pipeline, 2011
AEterna Zentaris Inc. – Combination Treatment Modalities in Pipeline, 2011
AEterna Zentaris Inc. – Pipeline By Therapeutic Class, 2011
AEterna Zentaris Inc. - Pipeline By Target, 2011
AEterna Zentaris Inc. – Pipeline By Route of Administration, 2011
AEterna Zentaris Inc. – Pipeline By Molecule Type, 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS